Home » Newsletters » BioWorld Science

BioWorld Science

March 30, 2009

View Archived Issues

Captisol-Enabled budesonide/azelastine combination nasal spray effective, convenient

Novel diacylglycerol acyltransferase type 1 inhibitors developed by AstraZeneca

Takeda describes novel substituted pyrazole derivatives for cancer treatment

Cortex Pharmaceuticals claims novel bicyclic amides that enhance synaptic responses

Bristol-Myers Squibb presents novel glucokinase activators

Lilly presents novel substituted piperazinyl pyrazines and pyridines as 5-HT7 receptor antagonists

Allos submits NDA to FDA for pralatrexate in relapsed or refractory PTCL

Poniard completes patient enrollment in phase III SPEAR clinical trial of picoplatin in SCLC

Endo initiates offer to purchase its 6.25% convertible senior notes due 2009

Galapagos advances GLPG-0259 into the clinic for rheumatoid arthritis

Takeda applies for additional indication in Japan for Takepron in gastric and duodenal ulcers

E.U. accepts for review The Medicines Company's MAA for Cleviprex in acute hypertension

Oxygen Biotherapeutics adds Israeli clinical trial sites to phase II study of Oxycyte in TBI

FDA accepts for filing and review Spectrum's sNDA for Fusilev in colorectal cancer

VGX completes phase I multiple ascending-dose study of VGX-1027

HemaQuest receives orphan medicinal designations for hemoglobin disorders

Lux Biosciences reports results from Luveniq phase III LUMINATE trials in uveitis

Akela and Nventa to merge

Biotie initiates clinical trial with proprietary VAP-1 antibody in psoriasis

AMP-activated protein kinase regulator may be useful for the treatment of metabolic disorders

Novel beta3-adrenergic receptor agonists with increased selectivity discovered

Potent and efficacious PI3 kinase inhibitors identified for cancer treatment

Parvovirus H-1PV shows potential in pancreatic ductal adenocarcinoma therapy

Cubist initiates phase II ecallantide trial for blood loss reduction during surgery

Osiris discontinues enrollment in Crohn's study due to concerns with trial design

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...